Japan’s Takara Bio Submits Clinical Trial Notification To PMDA For Leukemia Gene Therapy
This article was originally published in PharmAsia News
Japan-based Takara Bio submitted a clinical trial notification to Japan's Pharmaceutical and Medical Device Agency for TBI-0301, a gene therapy to treat leukemia. TBI-0301 is a retroviral vector to be used in donor lymphocyte transfusion to treat relapsed leukemia and to stabilize side effects caused by immune reactions from donor lymphocytes. (Click here for more - Japanese language)
You may also be interested in...
Chugai is pursuing further Japanese litigation over generic rivals to its Edirol brand, this time concerning the eldecalcitol ingredient produced by Nissan Chemical.
The European Commission has unexpectedly concluded that CBD should not be considered as a drug opening up the path to a regulated EU market for the cannabinoid as a novel food.
As Apotex names its new US president and CEO, Akorn puts together a fresh board of directors following bankruptcy proceedings. Stada has made new appointments in Germany, while Siegfried makes significant changes in its leadership roles.